MREO

Mereo BioPharma Group plc (MREO) Risks & Opportunities Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-09-01

Overall Score

Balance Sheet Liquidity

Strong liquidity with a current ratio of 5.88 and cash ratio of 5.31.

Very low leverage, with debt-to-equity at 0.04 and debt-to-assets at 0.03.

Net current asset value remains positive at $27.3M, supporting downside protection.

Profitability Cash Flow

Operating performance remains deeply negative, with ROA at -0.81 and ROIC at -1.13.

Cash generation is still negative, with free cash flow per share at -0.16 and operating cash flow per share at -0.16.

Interest coverage remains extremely weak at -393.7, reflecting ongoing losses.

Valuation Downside Protection

The company still screens as asset-backed, with tangible book value per share at 0.18 and book value per share at 0.18.

Price-to-book is 1.50, which is not expensive for a cash-rich balance sheet.

Negative earnings and cash flow metrics limit the usefulness of earnings-based valuation multiples.

Operational Business Risk

The business remains unprofitable, with zero margins across gross, operating, and net profit lines in the latest data.

A very long cash conversion cycle of -456.3 days is distorted by unusually high payables, which can be a working-capital risk if it normalizes.

No recent news was provided, so there is no new catalyst to reduce execution or business-model risk.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Mereo BioPharma Group plc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →